Last reviewed · How we verify
Sustained-release oral dalfampridine
Dalfampridine is a potassium channel blocker that enhances action potential conduction in demyelinated nerve fibers by prolonging the duration of the action potential.
Dalfampridine is a potassium channel blocker that enhances action potential conduction in demyelinated nerve fibers by prolonging the duration of the action potential. Used for Multiple sclerosis with walking impairment (marketed as Ampyra/Fampyra).
At a glance
| Generic name | Sustained-release oral dalfampridine |
|---|---|
| Also known as | Prolonged-release Fampridine, Ampyra |
| Sponsor | Sheba Medical Center |
| Drug class | Potassium channel blocker |
| Target | Voltage-gated potassium channels (Kv channels) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Dalfampridine blocks voltage-gated potassium channels, which slows repolarization of nerve membranes and allows action potentials to propagate more effectively across demyelinated axons in multiple sclerosis. This mechanism improves nerve conduction velocity and can restore some motor function in MS patients with walking impairment. The sustained-release formulation allows for twice-daily dosing with improved tolerability.
Approved indications
- Multiple sclerosis with walking impairment (marketed as Ampyra/Fampyra)
Common side effects
- Seizures
- Urinary tract infection
- Insomnia
- Dizziness
- Headache
- Nausea
- Asthenia/fatigue
Key clinical trials
- Study of Oral Fampridine-SR in Multiple Sclerosis (PHASE3)
- Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury (PHASE3)
- Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS (PHASE4)
- Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sustained-release oral dalfampridine CI brief — competitive landscape report
- Sustained-release oral dalfampridine updates RSS · CI watch RSS
- Sheba Medical Center portfolio CI